Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Operating Expenses (2023 - 2025)

Monte Rosa Therapeutics' Operating Expenses history spans 3 years, with the latest figure at $52.5 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 10.19% year-over-year to $52.5 million; the TTM value through Dec 2025 reached $177.9 million, up 13.49%, while the annual FY2025 figure was $177.9 million, 13.49% up from the prior year.
  • Operating Expenses reached $52.5 million in Q4 2025 per GLUE's latest filing, up from $45.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $52.5 million in Q4 2025 to a low of $34.3 million in Q1 2023.
  • Average Operating Expenses over 3 years is $39.8 million, with a median of $37.3 million recorded in 2023.
  • The largest YoY upside for Operating Expenses was 36.66% in 2024 against a maximum downside of 3.31% in 2024.
  • A 3-year view of Operating Expenses shows it stood at $34.9 million in 2023, then soared by 36.66% to $47.6 million in 2024, then rose by 10.19% to $52.5 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Operating Expenses are $52.5 million (Q4 2025), $45.7 million (Q3 2025), and $38.7 million (Q2 2025).